The ShinesRooms.com Provides Stock Research on Hemispherx Biopharma Inc. and Gilead Sciences Inc.
New York City, New York -- Biotech sector is one of the most competitive sectors around. The fortunes of a biotech company can be made or broken on the back of just one drug candidate. While a blockbuster drug candidate can help the company to boost its stock price as is the case of Gilead Sciences Inc. (NASDAQ: GILD), other companies may lose their market value. Hemispherx Biopharma Inc. (AMEX: HEB) proves this point as it continues to bleed in stock market, following the decline of its chronic fatigue drug Ampligen by FDA. Gilead is also increasing its presence in newer segments like Hepatitis and cancer treatments, which will help it in increasing its revenue streams.
Access our free reports on Hemispherx Biopharma Inc. and Gilead Sciences Inc. Traders can also connect to our Wall Street Trading Floor where our research desk and market pros are standing between 8:50 am to 4:15 pm ET at
Hemispherx Biopharma Inc. stock lost more than 35 percent of its value in the past 12 months and the situation has been made dire by the fact that its chronic fatigue drug Ampligen failed to receive FDA approval. As bad as it may sound, the outcome is not entirely unexpected. The drug has already been rejected once before. Hemispherx Biopharma also chose a short cut for resubmitting the drug for approval. However, it plans to appeal against the rejection.
Hemispherx Biopharma specializes in developing immune system related therapies. Approval of Ampligen could have drastically changed the company’s fortunes as currently there is no drug available for treating Chronic Fatigue Syndrome. Hemispherx Biopharma now faces uncertain future despite its intention to file for appeal. The stock is currently trading close to its 52-week low and despite the discounted pricing, it is not attractive option for investment.
Conversely, Gilead Sciences Inc. is having a good time as its stock is on the roll and the company reported healthy fourth quarter results. The company grew its quarterly profit by 15 percent to $762.5 million, whereas its revenue stood at $2.59 billion, up 18 percent. Its stock appreciated 50 percent in the past 12 months and is likely to perform in the future as well as Gilead reported 16 percent increase in its annual revenue.
Gilead Sciences is also diversifying itself. The company has leadership position in HIV market and is now planning to improve its hold in Hepatitis segment. Hepatitis cases are on the rise and thus the segment offers a lucrative option for Gilead Sciences. It is currently developing Sofosbuvir for Hepatitis C and the drug has high chances of receiving FDA approval later this year.
The company is not only growing organically but also through acquisitions. Gilead Sciences recently acquired YM BioSciences for $510 million. Though, the company paid 78 percent premium to YM BioSciences, the acquisition will help the company to augment its oncology therapy portfolio. The company also invested $11.2 billion to acquire Pharmasset, which helped it to augment its position in Hepatitis market.
Gilead Sciences stock grew 42 percent in last one year and is expected to keep up the momentum. The company also recently split its stock in two for one ratio. Gilead Sciences has strong balance sheet with $1.7 billion in cash as on the end of its third quarter.
Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape. ShinesRooms.com is the Ultimate Trading Environment for investors. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing. www.ShinesRooms.com
To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html
Michael Thomas Smith
Leave a comment...